Competitive Salary: EMBL: Internship - BioinformaticsLocation:Heidelberg, GermanyStaff Category:TraineeDuration:3 - 6 monthsClosing Date:15 July 2018Reference Number:HD_01332J Germany (DE)

Notice NOT-CA-18-077 from the NIH Guide for Grants and Contracts

Bachelor's degree in biomedical, social, behavioral sciences, public health, bioinformatics, computer science or related field, required....
From University of Wisconsin–Madison - Fri, 15 Jun 2018 00:58:04 GMT - View all Madison, WI jobs

Science nerds please apply. DNAnexus combines expertise in cloud computing and bioinformatics to create the global network for genomics, operating in North...
From DNAnexus - Thu, 14 Jun 2018 20:33:02 GMT - View all Mount View, WI jobs

Funding Opportunity PAR-18-831 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from the scientific community to support outstanding research in the area of epitranscriptomics, i.e., the chemical modifications of RNA. Evidence is accumulating that RNA modifications regulate the function of both coding and noncoding RNAs, suggesting that these modifications are involved in both development, and in health and disease. Yet the extent and types of these RNA modifications as well as their roles in particular biological processes remain either poorly understood or not known. The goal of the FOA is to promote research into the role of RNA chemical modifications in the initiation and progression of various developmental processes and disease states and conditions relevant to the scientific mission of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

Funding Opportunity PAR-18-830 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from the scientific community to support outstanding research in the area of epitranscriptomics, i.e., the chemical modifications of RNA. Evidence is accumulating that RNA modifications regulate the function of both coding and noncoding RNAs, suggesting that these modifications are involved in both development, and in health and disease. Yet the extent and types of these RNA modifications as well as their roles in particular biological processes remain either poorly understood or not known. The goal of the FOA is to promote research into the role of RNA chemical modifications in the initiation and progression of various developmental processes and disease states and conditions relevant to the scientific mission of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the National Cancer Institute (NCI), and the National Eye Institute (NEI).

Notice NOT-OD-18-192 from the NIH Guide for Grants and Contracts

Notice NOT-OD-18-191 from the NIH Guide for Grants and Contracts

Notice NOT-OD-18-190 from the NIH Guide for Grants and Contracts

Notice NOT-NS-18-072 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AI-18-023 from the NIH Guide for Grants and Contracts. This initiative will support research to determine the roles and interactions of immune cells at the maternal-fetal interface throughout pregnancy, including mechanisms of responses to vaccination and infection that protect the fetus and that may influence fetal immune system development.

Notice NOT-AI-18-040 from the NIH Guide for Grants and Contracts

Notice NOT-NS-18-058 from the NIH Guide for Grants and Contracts

Notice NOT-NS-18-057 from the NIH Guide for Grants and Contracts

Notice NOT-NS-18-069 from the NIH Guide for Grants and Contracts

Negotiable: Paramount Recruitment: Java Developer - Bioinformatics London Paramount are working in partnership with Genomics England to expand their team in order to deliver success wi London, England

Competitive with benefits, subject to skills and experience: The Francis Crick Institute: We are seeking a highly motivated and collaborative Postdoctoral Fellow to develop computational approaches for characterizing genome-wide changes. London (Central), London (Greater) (GB)

Funding Opportunity PAR-18-828 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications for investigator-initiated early phase clinical trials of natural products (i.e., botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify further clinical testing. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. This FOA will provide up to 3 years support for studies to replicate the impact of the natural product on the biological signature(s) when used by humans and assess whether there is an association between the degree of the impact on the biological signature and functional or clinical outcomes in a patient population. Applications can design studies to determine how to optimize the impact of the natural product on the biological signature by (1) optimizing the delivery of the natural product by dose or formulation; (2) combine the natural product with another treatment approach that is known to impact the same biological signature; or (3) study the impact of the natural product in a target population that is more responsive. Clinical trials submitted under this FOA are expected to be hypothesis based, milestone-driven, and directly related to the research priorities and mission of NCCIH. This R33 funding mechanism is intended to accelerate the translation of emerging basic science findings about natural products into early stage clinical testing to determine whether continued clinical research is warranted. This FOA will not support efficacy or effectiveness trials, nor will it support trials to test natural products for the treatment or prevention of cancer.

Funding Opportunity PAR-18-829 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications for investigator-initiated early phase clinical trials of natural products (i.e., botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify further clinical testing. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. This FOA will provide up to two years (R61 phase) of support for milestone-driven testing of bioavailability, pharmacokinetics, and assessment of the natural products effect (i.e., measure of mechanism of action) when used by humans on a biological signature(s). If milestones in the R61 phase are achieved, up to 3 years of additional support (R33 phase) may be awarded to replicate the impact of the natural product on the biological signature(s) when used by humans and assess whether there is an association between the degree of the impact on the biological signature and functional or clinical outcomes in a patient population. Applications can design R33 studies to determine how to optimize the impact of the natural product on the biological signature by (1) optimizing the delivery of the natural product by dose or formulation; (2) combine the natural product with another treatment approach that is known to impact the same biological signature; or (3) study the impact of the natural product in a target population that is more responsive. Clinical trials submitted under this FOA are expected to be hypothesis based, milestone-driven, and directly related to the research priorities and mission of NCCIH. This R61/R33 funding mechanism is intended to accelerate the translation of emerging basic science findings about natural products into early-stage clinical testing to determine whether continued clinical research is warranted. This FOA will not support efficacy or effecti

Funding Opportunity RFA-CA-18-015 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits applications from institutions/organizations to participate as "Research Bases" for the National Cancer Institute (NCI)-supported Community Oncology Research Program (NCORP). NCOR P is a community-based research network that: Designs and conducts clinical trials and other human subject studies for adults and children in cancer prevention, control, screening, and care delivery, as well as quality-of-life studies embedded within treatment trials; Incorporates unique research needs of diverse populations such as, adolescents and young adults (AYAs), and the elderly; racial and ethnic minorities; sexual and gender minorities; and rural residents into studies and takes steps to enhance participation of these groups; Enhances patient and provider access to treatment and imaging trials conducted under the National Clinical Trials Network (NCTN); Integrates cancer disparities research within the community network. NCORP consists of three components each with its own FOA: NCORP Research Bases (covered by this FOA); NCORP Community Sites; and NCORP Minority/Underserved Community Sites. The NCORP Research Bases will design and conduct cancer clinical trials and care delivery research studies as well as manage and analyze the data and report the research results.